This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Non-neuropathic heredofamilial amyloidosis (familial Mediterranean fever)Non-neuropathic Heredofamilial Amyloidosis (Familial Mediterranean Fever)

ItemDetails
A. ICD-10 codeE85.0 | Special Copayment Reduction: V121
B. SynonymsHereditary amyloid nephropathy, non-neuropathic heredofamilial amyloidosis, Familial Mediterranean Fever (FMF), recurrent fever syndrome, Mediterranean periodic fever, periodic peritonitis, MEFV-associated autoinflammatory disease, AA amyloidosis (complication of FMF)
C. Adult onsetMay first present in adulthood — FMF attacks mostly begin before age 20, but the first attack may occur in adulthood, and AA amyloidosis may first be diagnosed in adulthood as proteinuria or renal failure even without recurrent attacks
1. HistoryFirst description by Siegal in 1945; discovery of the MEFV gene (1997); history of establishing colchicine treatment
2. CausesMEFV gene mutation → abnormal pyrin protein → dysregulation of the inflammasome → IL-1β oversecretion → recurrent inflammatory attacks → AA amyloidosis
3. GeneticsAutosomal recessive; MEFV gene (16p13.3); 5 major variants M694V·M680I·M694I·V726A·E148Q
4. General epidemiologyPrevalence 1/200~1/1,000 in Mediterranean and Middle Eastern ethnic groups (Turkish, Armenian, Arab, Sephardic Jewish); rare in Asia but reported
5. PathophysiologyLoss of pyrin function → NLRP3/pyrin inflammasome hyperactivation → caspase-1 activation → IL-1β·IL-18 secretion → inflammatory attacks of the peritoneum, joints and pleura; chronically high SAA → deposition of AA amyloid fibrils
6. SymptomsRecurrent fever (38~40°C, 12~72 hours), abdominal pain (peritonitis), chest pain (pleuritis), arthritis, erysipelas-like skin rash; in the long term, AA renal amyloidosis
7. SignsSigns of peritonitis (during attacks), elevated CRP·SAA·ferritin (may persist between attacks), proteinuria (amyloidosis)
8. ScreeningCRP/SAA measurement; clinical score (Tel Hashomer criteria); MEFV gene testing
9. DiagnosisTel Hashomer clinical diagnostic criteria; confirmation of MEFV variants; Congo red staining of tissue biopsy (amyloidosis)
10. TreatmentDaily colchicine (key to preventing attacks and amyloidosis); IL-1 blockers (anakinra, canakinumab) — for colchicine-resistant patients
11. PrognosisColchicine treatment can prevent attacks and amyloidosis; without treatment, AA amyloidosis progressing to renal failure is the main cause of death
12. PreventionGenetic counseling; early initiation of colchicine; SAA monitoring; preventing progression of amyloidosis
13. References10 key references

1. History

Non-neuropathic heredofamilial amyloidosis associated with Familial Mediterranean Fever (FMF) is a disease long observed in ethnic groups of the Mediterranean region. In 1945, the American pediatrician Sheppard Siegal described recurrent attacks of fever, abdominal pain and chest pain in Armenian Jewish patients and named the condition "benign paroxysmal peritonitis." He initially judged that these attacks followed a benign course, but later studies revealed that renal failure due to amyloidosis is a serious complication.

In 1955, Heller and Sohar described patients in Israel with a similar clinical picture and proposed the name "familial Mediterranean fever." This name reflects the epidemiological feature that the disease occurs predominantly in ethnic groups of the Mediterranean region. In 1972, Mamou and Cattan systematically described the association between FMF and AA amyloidosis, establishing amyloidosis as the main cause of end-stage renal failure in untreated FMF.

In 1972, Goldfinger first reported that colchicine prevents FMF attacks. Subsequent clinical trials confirmed the effect of colchicine in preventing attacks and inhibiting the progression of amyloidosis, and colchicine became the standard treatment for FMF. This was a very important milestone in the history of treating autoinflammatory diseases.

In 1997, international collaborative research teams from France and Israel (the French FMF Consortium and the International FMF Consortium) identified MEFV, the causative gene of FMF, on the short arm of chromosome 16 (16p13.3) and characterized the pyrin protein it encodes. This discovery made possible an understanding of the molecular pathophysiology of FMF and diagnosis based on genetic testing. After the 2000s, as the mechanism by which pyrin regulates the inflammasome was elucidated, IL-1β inhibitors were introduced as a new treatment option.

2. Causes

The direct cause of FMF and the associated AA amyloidosis is dysfunction of the pyrin protein due to pathogenic variants in the MEFV gene. Pyrin (also called marenostrin) is a protein of 781 amino acids expressed mainly in granulocytes and monocytes. Pyrin consists of a B30.2 (SPRY) domain, a B-box zinc finger domain, a coiled-coil domain and a PYRIN domain (PYD), and most pathogenic variants are concentrated in the B30.2 domain.

Normal pyrin functions as a key molecule in inflammasome regulation. In particular, it regulates caspase-1 activation via ASC (apoptosis-associated speck-like protein containing a CARD). When pyrin is dephosphorylated by bacterial toxins (Rho GTPase-inhibiting toxins), the pyrin inflammasome is activated, leading to maturation and secretion of IL-1β and IL-18 via caspase-1, and at the same time gasdermin D-mediated pyroptosis is induced.

In FMF, MEFV variants are located mainly in the B30.2 domain of pyrin, a domain involved in regulating inactivation through pyrin phosphorylation (dependent on the RhoA-PKN1/2 pathway). Mutant pyrin is not inactivated as readily under normal conditions, so the inflammasome becomes hyperactivated, and excessive IL-1β secretion causes recurrent inflammatory attacks.

Chronic, recurrent inflammatory attacks cause a sustained rise in blood SAA (serum amyloid A protein, an acute-phase protein). SAA1·2 are acute-phase reactants that circulate bound to high-density lipoprotein (HDL). In a chronically high-SAA environment, SAA fragments are deposited in organ tissues (especially the renal glomeruli and interstitium) as insoluble amyloid fibrils with a beta-sheet structure, resulting in AA amyloidosis. SAA1 gene polymorphisms (especially the SAA1α isoform) are also modifiers of amyloidosis risk.

3. Genetics

FMF is an autosomal recessive (AR) genetic disease. The causative gene, MEFV, is located on the short arm of chromosome 16 (16p13.3) and consists of 10 exons. More than 300 variants in MEFV have been reported to date, but only some of them have established pathogenicity.

The 5 most common and clinically important variants are as follows: M694V (exon 10, methionine→valine), M680I (exon 10), M694I (exon 10), V726A (exon 10) and E148Q (exon 2). These 5 variants account for more than about 85% of all FMF patients. M694V homozygosity (M694V/M694V) is the most severe form of FMF, with the highest attack frequency, severity and risk of amyloidosis. M694V is the most common variant in Turkish, Armenian and North African Arab patients.

E148Q is the mildest variant, and some experts do not regard E148Q alone as a pathogenic variant, classifying it instead as a carrier state or background polymorphism. Therefore caution is needed in interpretation when E148Q alone is found in a patient with clinically suspected FMF.

Carrier frequency is very high in high-risk ethnic groups. About 1/5 of Turks, about 1/7 of Armenians, about 1/5 of Arabs and about 1/5 of non-Ashkenazi Jews are estimated to be carriers. This high carrier frequency is thought to reflect a historical selective advantage (heterozygote advantage) against malaria or other pathogens. In East Asians, MEFV variants are rare, but asymptomatic mutations or mild variants are sometimes found.

In some patients with a clinically typical FMF phenotype, MEFV variants are found in only one allele or not at all. To explain this, deep intronic variants, large deletions and the like are being investigated. Clinical diagnostic criteria (the Tel Hashomer criteria) remain important alongside genetic test results.

4. General epidemiology

FMF is the most common monogenic autoinflammatory disease in the world. It occurs predominantly in particular ethnic groups of the Mediterranean and Middle East regions. Prevalence is highest in Turks, Armenians, Arabs, non-Ashkenazi (Sephardic) Jews and Greeks.

In Turkey, the prevalence of FMF is about 1/1,000, with an estimated 80,000~100,000 patients. In Armenia and the Armenian diaspora it is higher, at about 1/200. In Israel, the prevalence among non-Ashkenazi Jews is about 1/200~1/1,000. The number of FMF patients worldwide is estimated at more than 150,000.

In East Asia, including Korea, FMF is rare, but rare cases have been reported. In Korea too, FMF should be included in the differential diagnosis of patients presenting with recurrent fever and multi-organ inflammatory attacks. Patients with mild disease due to atypical MEFV variants or with monoallelic variants may be being misdiagnosed in East Asia.

Onset is before age 20 in about 90%, and the first attack begins before age 5 in about 50%. The sex ratio is almost equal or slightly male-predominant. AA amyloidosis is reported to develop in 25~60% of untreated FMF patients (varying by region and genotype).

5. Pathophysiology

The core pathophysiology of FMF is excessive secretion of IL-1β and IL-18 due to unregulated activation of the pyrin inflammasome.

Under normal conditions, pyrin is kept in an inactive state through phosphorylation by the RhoA-PKN1/2 kinase pathway. When bacterial Rho GTPase-inhibiting toxins block this pathway, pyrin is dephosphorylated and switches to an active state, binding ASC to form the inflammasome complex. This complex cleaves pro-caspase-1 into active caspase-1, and caspase-1 processes pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18, which are secreted from the cell. At the same time, caspase-1 cleaves gasdermin D to form plasma membrane pores, thereby inducing pyroptosis (inflammatory cell death).

In FMF, pyrin with MEFV B30.2 domain variants is less effectively inhibited by normal PKN1/2-mediated phosphorylation. As a result, the pyrin inflammasome is activated even by lower levels of stimulation, leading to excessive IL-1β secretion. Consequently, excessive neutrophil infiltration and acute inflammatory reactions (attacks) occur in the peritoneum, pleura, joints, testes and elsewhere.

With each recurrent inflammatory attack, SAA1·SAA2 are synthesized in large amounts in the liver as an acute-phase response. In patients with persistent low-grade inflammation even between attacks, SAA does not fully normalize. In a chronically high-SAA environment, SAA fragments are deposited in tissues throughout the body as AA amyloid fibrils. When AA amyloid accumulates in the renal glomeruli and interstitium, proteinuria without glomerulonephritis begins, and with progression nephrotic syndrome and chronic renal failure develop. Besides the kidneys, AA amyloid can be deposited in the spleen, liver, adrenal glands, thyroid and intestine.

6. Symptoms

Recurrent febrile attacks: the most characteristic symptom of FMF. Body temperature rises abruptly to 38~40°C, and attacks usually last 12~72 hours. Attacks resolve spontaneously, and being completely asymptomatic between attacks is a hallmark of typical FMF. Attack frequency varies between individuals, from less than once a month to 1~2 times a week.

Abdominal pain (peritonitis): the most common accompanying symptom, occurring in more than 90% of FMF patients. Diffuse abdominal pain across the peritoneum, abdominal rigidity and rebound tenderness present as acute peritonitis. At the first attack, patients may be mistaken for acute appendicitis, perforated peptic ulcer and the like and undergo unnecessary surgery. Abdominal pain usually appears at the same time as or after the fever and peaks within a few hours.

Chest pain (pleuritis/pericarditis): chest pain due to pleural irritation occurs in about 40~50%. It presents as unilateral or bilateral pleuritis and may be accompanied by pleural effusion. Pericarditis also occurs rarely.

Arthritis: joint symptoms occur in about 50~60%. Monoarthritis or oligoarthritis affecting large joints of the lower limbs, such as the knee and ankle, is typical. It is mostly nondestructive and resolves with the attack. Hip arthritis can become a persistent abnormality.

Skin rash: in about 25~40%, an erysipelas-like erythema (ELE) rash appears on the lower limbs, especially around the ankles. It takes the form of warm, tender, well-demarcated erythematous nodules.

Symptoms of AA amyloidosis: the first symptom of renal AA amyloidosis is asymptomatic proteinuria. With progression, nephrotic syndrome (edema, hypoalbuminemia, hyperlipidemia, heavy proteinuria), declining renal function and end-stage renal failure develop. Amyloidosis can develop even without attacks in patients with persistent low-grade inflammation.

7. Signs

Physical signs during attacks: signs of peritonitis are prominent. Abdominal tenderness (especially in the left lower abdomen or the whole abdomen), rebound tenderness and abdominal rigidity (board-like rigidity) appear. Bowel sounds are decreased or absent. High fever (38~40°C) accompanies these. With pleuritis, a pleural friction rub, pleuritic chest pain and breath-holding are observed. During joint attacks, redness, swelling, warmth and limited movement of the affected joint appear. Attacks resolve spontaneously and disappear completely within 24~72 hours.

Signs between attacks: in typical FMF there are no abnormal findings between attacks. However, when amyloidosis has progressed, hypertension, edema and pallor (anemia) are observed. Splenomegaly may occur due to amyloid deposition.

Laboratory signs: during attacks, leukocytosis, a sharp rise in CRP·ESR, a rise in serum SAA of tens of times or more, and elevated fibrinogen·ferritin appear. The risk of amyloidosis is high in patients whose CRP and SAA do not fully normalize even between attacks. When amyloidosis develops, urinary protein (spotty proteinuria → nephrotic-range proteinuria) and elevated serum creatinine appear. 24-hour urine protein or the random protein/creatinine ratio is the screening indicator.

Histopathological signs: observation of apple-green birefringence on Congo red staining of a kidney, rectal, abdominal fat or gingival biopsy confirms amyloidosis. AA amyloid is confirmed by immunohistochemistry with anti-SAA antibodies.

8. Screening

There is no specific newborn screening test for FMF. A stepwise screening approach is applied once FMF is clinically suspected.

Clinical screening criteria (Tel Hashomer criteria): consist of 3 major criteria (attacks of febrile peritonitis, pleuritis or pericarditis; monoarthritis with erysipelas-like skin rash; FMF confirmed in a family member without a valid family history) and minor criteria (recurrent fever, arthralgia, erysipelas-like rash, family history). FMF is diagnosed on screening when there is 1 major criterion or 2 or more minor criteria.

Eurofever/PRINTO diagnostic criteria (2019): more quantified recent criteria that provide sets of clinical criteria for MEFV-positive and MEFV-negative groups respectively, enabling more accurate diagnosis.

Measurement of acute-phase reactants: serum SAA, CRP and white blood cell count are measured during and between attacks. If SAA between attacks persistently exceeds 10 mg/L, the risk of developing amyloidosis is high, and increasing the colchicine dose or adding a biologic should be considered.

MEFV gene screening: in clinically suspected patients, testing for the 5 major MEFV variants or sequencing of all exons is performed. Genetic test results are interpreted together with clinical symptoms, and when E148Q alone is found, the clinical context is fully considered.

9. Diagnosis

The diagnosis of FMF is based on clinical criteria and supplemented by genetic testing.

Tel Hashomer clinical criteria: definite: 2 or more major criteria, or 1 major criterion + 2 or more minor criteria. Probable: 1 major criterion, or 3 or more minor criteria. Response to colchicine treatment is strong evidence supporting the diagnosis.

Eurofever/PRINTO criteria (2019): a method that applies clinical criteria separately to MEFV-positive cases (presence of biallelic pathogenic variants) and negative cases. Can be used in both pediatric and adult patients.

MEFV gene testing: a panel test of at least the 5 major variants, including exon 10 (M694V, M680I, M694I, V726A, etc.) and exon 2 (E148Q) variants, or sequencing of all exons. Caution: a negative MEFV gene test does not exclude FMF, and FMF is sometimes diagnosed clinically even with only a monoallelic variant.

Diagnosis of AA amyloidosis: confirmation of amyloidosis is needed in FMF patients with proteinuria. Apple-green birefringence is confirmed under polarized light microscopy after Congo red staining of a tissue biopsy (kidney, rectal mucosa, abdominal subcutaneous fat). AA amyloid is confirmed by immunohistochemistry (anti-SAA antibody). Kidney biopsy clearly shows amyloid deposition in the glomeruli, vessel walls and interstitium.

Differential diagnosis: must be differentiated from TRAPS (TNF receptor-associated periodic syndrome), CAPS (cryopyrin-associated periodic syndrome), PFAPA syndrome, adult-onset Still disease (AOSD), other causes of acute peritonitis (appendicitis, perforated peptic ulcer), reactive arthritis, polymyalgia rheumatica and others.

10. Treatment

Colchicine: the foundation of treatment for FMF and for preventing the resulting AA amyloidosis. The proposed mechanism is inhibition of neutrophil activation and migration through inhibition of microtubule polymerization, and inhibition of pyrin inflammasome activation. Adult dose: 1~2 mg/day orally (usually as a single dose at bedtime or in divided doses). Pediatric dose: weight-based (0.5~1 mg/day; under 5 years 0.5 mg, 5~10 years 1 mg, 10 years and older 1.5~2 mg). The treatment goals are reducing the frequency and intensity of attacks and normalizing SAA between attacks (less than 10 mg/L). Adverse effects: nausea, diarrhea and abdominal pain are common and dose-dependent. Sperm toxicity (with long-term high-dose use), myopathy (rare, but the risk increases with combined colchicine + statin use). Colchicine is known to be relatively safe to use even during pregnancy, but caution is needed.

IL-1 blockers: used in patients with colchicine intolerance or colchicine resistance (attacks persisting at least once a month or failure to normalize SAA even at 1.5~2 mg/day). - Anakinra (IL-1Ra, recombinant human interleukin-1 receptor antagonist): 100 mg/day by subcutaneous injection. Effective for controlling acute attacks and preventing attacks. Approved for the FMF indication in some European countries. - Canakinumab (anti-IL-1β monoclonal antibody): 150 mg by subcutaneous injection every 8 weeks. A complete response rate of 61% was confirmed in colchicine-resistant FMF in a clinical trial (CLUSTER study). FDA approval in 2021.

Treatment when amyloidosis progresses: in patients with progressive renal amyloidosis, RAAS inhibitors (ACE inhibitors or ARBs) are used to reduce proteinuria and protect renal function. In end-stage renal failure, dialysis or kidney transplantation is needed. Colchicine is continued after transplantation.

11. Prognosis

The prognosis of FMF patients depends greatly on whether they are treated and whether AA amyloidosis develops.

Before colchicine treatment was introduced, the incidence of amyloidosis was very high in FMF patients, especially M694V homozygotes, and death from renal failure was the main cause. Some studies in the Middle East reported that 25~60% of FMF patients progressed to amyloidosis before treatment.

With colchicine 1~2 mg/day, complete control of attacks is achieved in about 65~75% and partial control in 25~30%. More importantly, colchicine treatment has been shown to markedly reduce the development of AA amyloidosis and to inhibit the progression of existing amyloidosis. In patients whose SAA between attacks normalizes with colchicine, the risk of amyloidosis falls dramatically.

In colchicine-resistant patients (about 5~10%), the introduction of IL-1 blockers has made it possible to control attacks and normalize SAA, further improving the prognosis. Even in patients whose amyloidosis has already progressed, sufficient suppression of inflammation with colchicine or IL-1 blockers can slow the rate of renal deterioration. In end-stage renal failure, kidney transplantation shows outcomes similar to those in the general population, and colchicine is continued after transplantation to prevent amyloid recurrence in the transplanted kidney.

12. Prevention

Preventing FMF attacks and preventing progression to AA amyloidosis are the main goals of treatment.

Early initiation of colchicine: starting colchicine as early as possible in patients with confirmed or strongly clinically suspected FMF is the most important preventive strategy. Early treatment markedly reduces the risk of developing amyloidosis. Because the safety of colchicine is also established in pediatric patients, administration is started as soon as the diagnosis is confirmed.

SAA monitoring: even during colchicine treatment, serum SAA is measured regularly to check whether SAA between attacks has normalized (less than 10 mg/L). Even if attack frequency has decreased, persistently elevated SAA requires intensified treatment (increasing the colchicine dose or adding a biologic). An annual urine protein test detects early renal amyloidosis.

Genetic counseling: genetic counseling for FMF patients and carriers informs them of the risk of disease in their children and ensures that diagnosis and treatment are started quickly in case of early onset. When both parents are carriers, FMF develops in 25% of their children.

Environmental and lifestyle management: avoiding, as far as possible, known attack triggers such as severe physical fatigue, stress, infection, trauma and menstruation (in some women) helps reduce attack frequency. Balanced nutrition, a regular lifestyle and sufficient sleep are also important for maintaining general immune function.

Education and awareness: raising awareness of FMF symptoms among both patients and medical staff reduces diagnostic delay, and diagnostic awareness is especially important in atypical regions (including East Asia).

13. References

  1. Infevers: an online database for autoinflammatory mutations. Sarrauste de Menthière C et al. Nucleic Acids Res. 2003;31(1):282–285. PMID:12520003
  2. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. PMID:26802181
  3. Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78(8):1025–1032. PMID:31015314
  4. Georgin-Lavialle S, Hentgen V, Stankovic Stojanovic K, et al. Evidence-based recommendations from the French rare disease centers of excellence for familial Mediterranean fever. Orphanet J Rare Dis. 2020;15(1):80. PMID:32216818
  5. Gül A, Özdoğan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Rheumatol. 2015;67(8):2190–2200. PMID:26315020
  6. Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci. 2009;13(Suppl 1):51–53. PMID:19530408
  7. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. PMID:9288094
  8. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. PMID:9288758
  9. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314–324. PMID:21279990
  10. Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553–555. PMID:11464246